Studies of 1-(o-cyclopropylphenoxy)-3-isopropylamino-2-propanol, a new  -adrenergic blocking drug.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000605:Amino Alcohols / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D001783:Blood Flow Velocity; D001794:Blood Pressure / Q000187:drug effects*; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects*; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects*; D010042:Ouabain / Q000037:antagonists & inhibitors; D011433:Propranolol / Q000494:pharmacology; D013565:Sympatholytics / Q000494:pharmacology* / Q000633:toxicity; D014655:Vascular Resistance / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D000889:Anti-Arrhythmia Agents; D013565:Sympatholytics; D010042:Ouabain; D001285:Atropine; D011433:Propranolol; D007545:Isoproterenol